Polatuzumab vedotin is a targeted therapy known as an antibody-drug conjugate. It consists of a monoclonal antibody that specifically binds to CD79b, a protein found on the surface of B cells, including many lymphoma cells. Attached to this antibody is a chemotherapy drug called MMAE, which is a microtubule inhibitor.

When polatuzumab vedotin binds to CD79b on the cancer cell, it is taken inside the cell. Once inside, the linker between the antibody and MMAE is broken down, releasing MMAE directly into the cell. MMAE then interferes with the cell’s ability to divide by disrupting the microtubules, which are essential for cell division. This targeted delivery helps kill the lymphoma cells while limiting exposure of healthy cells to the chemotherapy component.

polatuzumab vedotin

Common brand names

Approved use in